HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Article

Ann Thorac Surg 1996;62:1058
© 1996 The Society of Thoracic Surgeons

---

Discussion

Discussion

The first 20% of the full text of this article appears below.

See also page 1051.

DR TODD K. ROSENGART (New York, NY): I congratulate you on a very interesting paper and certainly an innovative approach to enhancing the potential of transmyocardial revascularization. I will briefly present some information that my associates and I have developed regarding the angiogenic potential of vascular endothelial growth factor (VEGF) in vivo. Before we went to studies examining VEGF delivery in the myocardium, we wanted first to assess its angiogenic potential when delivered using an adenovirus vector. We used retroperitoneum as a target site for a number of reasons, including the fact that this tissue possesses a very low baseline level of vascularization.

In these experiments, we delivered 109 pfu/100 µL of adenovirus encoding for VEGF, which . . . [Full Text of this Article]

Related Article

One-Month Histologic Response of Transmyocardial Laser Channels With Molecular Intervention

Kirk J. Fleischer, Pascal J. Goldschmidt-Clermont, James D. Fonger, Grover M. Hutchins, Ralph H. Hruban, and William A. Baumgartner
Ann. Thorac. Surg. 1996 62: 1051-1058. [Abstract] [Full Text]